Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr et al. · Journal of Clinical Oncology · 2000
PURPOSE: To confirm the promising phase II results of docetaxel monotherapy, this phase III trial was conducted of chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC) who had previously failed platinum-containing chemotherapy. PATIENTS AND METHODS: A total of 373 patients were randomized to receive either docetaxel 100 mg/m(2) (D100) or 75 mg/m(2) (D75) versus a control regimen of vinorelbine or ifosfamide (V/I). The three treatment groups were well-balanced for key patient characteristics. RESULTS: Overall response rates were 10.8% with D100 and 6.7% with D75, each significantly higher than the 0.8% response with V/I (P =.001 and P =.036, respectively). Patients who received docetaxel had a longer time to progression (P =.046, by log-rank test) and a greater progression-free survival at 26 weeks (P =.005, by chi(2) test). Although overall survival was not significantly different between the three groups, the 1-year survival was significantly greater with D75 than with the control treatment (32% v 19%; P =.025, by chi(2) test). Prior exposure to paclitaxel did not decrease the likelihood of response to docetaxel, nor did it impact survival. There was a trend toward greater efficacy in patients whose disease was platinum-resistant rather than platinum-refractory and in patients with performance status of 0 or 1 versus 2. Toxicity was greatest with D100, but the D75 arm was well-tolerated. CONCLUSION: This first randomized trial in this setting demonstrates that D75 every 3 weeks can offer clinically meaningful benefit to patients with advanced NSCLC whose disease has relapsed or progressed after platinum-based chemotherapy.
Cited by 1,360 works. doi:10.1200/jco.2000.18.12.2354
Authors
- Frank V. Fossella
- Russell F. DeVore
- Ronald N. Kerr
- Jeffrey Crawford
- Ronald Natale
- Frank Dunphy
- Leonard A. Kalman
- Vincent A. Miller
- Jin Soo Lee
- Melvin Moore
- David R. Gandara
- Daniel D. Karp
- Everett E. Vokes
- Mark G. Kris
- Yong Deok Kim
- F. Gamza
- Luz Hammershaimb
References
- Reporting results of cancer treatment
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Cancer statistics, 1998
- Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
- Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
- Management strategies for recurrent non-small cell lung cancer.
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)
- Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
- Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients.